Organon and Braincells to collaborate in discovery and development of CNS drugs
BCI will use its proprietary technology in the area of neurogenesis - the process by which pre-existing stem cells in the adult human brain produce new brain tissue, including neurons - to identify neuroscience applications for compounds formerly in the Organon clinical-stage pipeline. When BCI determines the therapeutic utility for a drug candidate, the companies will work together to develop and reposition the drug for its new use.
"We can bring new life to compounds that might otherwise sit on the shelf," said James A. Schoeneck, BCI's CEO. "The collaboration with Organon is a validation of our drug selection technology and development capabilities. By focusing on compounds that have already been tested for safety in the clinic, we can accelerate drug development while minimizing risk."
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.